No, I'm not usually a deal valuation speculator. My comment of "We need a partner/buyout now" was an indication that I don't care what form a deal takes at this point in time. I have no idea what they may actually come up with and no basis to speculate on money.
In Reply to 'Lemoncat' Obviously all talk from the company as of late has been regarding partnership. My ears prick up when I hear you mention buyout.
I know you're not a big speculator on deal valuations. Would you indulge us on what you feel could be pulled on a buyout at this time? I won't ask you to tell me yours without telling you mine.
I'm thinking the following:
With the loss of Prurisol and apparent disinterest in ABSSSI, we'd probably be looking at a buyout in the $300 million to $500 million range with upside to $700 million if the buyer is particularly interested in Kevetrin.
“...we'd probably be looking at a buyout in the $300 million to $500 million range with upside to $700 million if the buyer is particularly interested in Kevetrin.”
Give us three and we’ll shout with glee! Give us five and we’re again alive!! Give us seven and we’re in Heaven!!!
News 
Market Data 
Discover 
